An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies.

Interleukin (IL)-17 plays a role in host defense against common extracellular pathogens, including fungi.1-3 Biologics that selectively target IL-17 have shown efficacy in the treatment of psoriasis.4,5.